PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Infectious Disease Unit, Department of System Medicine, Tor Vergata University and Hospital, Via Montpellier 1, 00133 Rome, Italy. Electronic address: marco.iannetta@uniroma2.it.\', \'Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University and Hospital, Via Montpellier 1, 00133 Rome, Italy.\', \'Infectious Disease Unit, Department of System Medicine, Tor Vergata University and Hospital, Via Montpellier 1, 00133 Rome, Italy.\', \'Department of Biomedicine and Prevention, Tor Vergata University and Hospital, Via Montpellier 1, 00133 Rome, Italy.\', \'Virology Unit, Department of Experimental Medicine, Tor Vergata University and Hospital, Via Montpellier 1, 00133 Rome, Italy.\', \'Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University and Hospital, Via Montpellier 1, 00133 Rome, Italy; Unit of Neurology, IRCCS Istituto Neurologico Mediterraneo NEUROMED, 86077 Pozzilli (Is), Italy.\']
?:citedBy
  • -1
?:creator
?:doi
  • S2211-0348(21)00424-710.1016/j.msard.2021.103157
?:doi
?:hasPublicationType
?:journal
  • Multiple sclerosis and related disorders
is ?:pmid of
?:pmid
?:pmid
  • 34418737
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.123
?:rankingScore_hIndex
  • 18
is ?:relation_isRelatedTo_publication of
?:title
  • T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all